@article{371f9272cfb44acdb282b4dd69c59722,
title = "Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer{\textquoteright}s disease",
abstract = "The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer{\textquoteright}s disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.",
author = "Liu, {Yu Hui} and Jun Wang and Li, {Qiao Xin} and Fowler, {Christopher J.} and Fan Zeng and Juan Deng and Xu, {Zhi Qiang} and Zhou, {Hua Dong} and Doecke, {James D.} and Villemagne, {Victor L.} and Lim, {Yen Ying} and Masters, {Colin L.} and Wang, {Yan Jiang}",
note = "Funding Information: The AIBL study (www.AIBL.csiro.au), a consortium between Austin Health, CSIRO, Edith Cowan University, the Florey Institute (The University of Melbourne), and the National Ageing Research Institute, has received partial financial support provided by the Alzheimer?s Association (United States), the Alzheimer?s Drug Discovery Foundation, an Anonymous foundation, the Science and Industry Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government?s Operational Infrastructure Support program, the McCusker Alzheimer?s Research Foundation, the National Health and Medical Research Council, and the Yulgilbar Foundation. Numerous commercial interactions have supported data collection and analysis. In-kind support has also been provided by the Sir Charles Gairdner Hospital, CogState Ltd., Hollywood Private Hospital, The University of Melbourne, and St Vincent?s Hospital. The Chongqing cohort study was partially supported by the National Natural Science Foundation of China (91749206 and 81625007 to Y.-J.W., 81671277 to J.D., and 81600936 to Y.-H.L.) and the Chinese Ministry of Science and Technology (2016YFC1306401) Publisher Copyright: Copyright {\textcopyright} 2021 The Authors, some rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2021",
month = jan,
day = "1",
doi = "10.1126/sciadv.abb0457",
language = "English",
volume = "7",
journal = "Science Advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science (AAAS)",
number = "1",
}